Antisense oligonucleotides for the treatment of dyslipidaemia

被引:92
|
作者
Visser, Maartje E. [1 ]
Witztum, Joseph L. [2 ]
Stroes, Erik S. G. [1 ]
Kastelein, John J. P. [1 ]
机构
[1] Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands
[2] Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA
关键词
Antisense oligonucleotides; Hypercholesterolaemia; ApoB; PCSK9; Lp(a); Mipomersen; Cardiovascular disease; DENSITY-LIPOPROTEIN CHOLESTEROL; LOWERS PLASMA-CHOLESTEROL; B SYNTHESIS INHIBITION; ADD-ON THERAPY; APOLIPOPROTEIN-B; LDL CHOLESTEROL; FAMILIAL HYPERCHOLESTEROLEMIA; MESSENGER-RNA; DOUBLE-BLIND; SERUM LDL;
D O I
10.1093/eurheartj/ehs084
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Antisense oligonucleotides (ASOs) are short synthetic analogues of natural nucleic acids designed to specifically bind to a target messenger RNA (mRNA) by WatsonCrick hybridization, inducing selective degradation of the mRNA or prohibiting translation of the selected mRNA into protein. Antisense technology has the ability to inhibit unique targets with high specificity and can be used to inhibit synthesis of a wide range of proteins that could influence lipoprotein levels and other targets. A number of different classes of antisense agents are under development. To date, mipomersen, a 2-O-methoxyethyl phosphorothioate 20-mer ASO, is the most advanced ASO in clinical development. It is a second-generation ASO developed to inhibit the synthesis of apolipoprotein B (apoB)-100 in the liver. In Phase 3 clinical trials, mipomersen has been shown to significantly reduce plasma low-density lipoprotein cholesterol (LDL-c) as well as other atherogenic apoB containing lipoproteins such as lipoprotein (a) [Lp(a)] and small-dense LDL particles. Although concerns have been raised because of an increase in intrahepatic triglyceride content, preliminary data from long-term studies suggest that with continued treatment, liver fat levels tend to stabilize or decline. Further studies are needed to evaluate potential clinical relevance of these changes. Proprotein convertase subtilisin/kexin-9 (PCSK9) is another promising novel target for lowering LDL-c by ASOs. Both second-generation ASOs and ASOs using locked nucleic acid technology have been developed to inhibit PCSK9 and are under clinical development. Other targets currently being addressed include apoC-III and apo(a) or Lp(a). By directly inhibiting the synthesis of specific proteins, ASO technology offers a promising new approach to influence the metabolism of lipids and to control lipoprotein levels. Its application to a wide variety of potential targets can be expected if these agents prove to be clinically safe and effective.
引用
收藏
页码:1451 / 1458
页数:8
相关论文
共 50 条
  • [1] Antisense oligonucleotides in the treatment of cancer
    Dorr, FA
    ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1999, 9 (04): : 391 - 396
  • [2] Antisense Oligonucleotides for the Treatment of Dyslipidemia
    Gouni-Berthold, I.
    Berthold, H. K.
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (09) : 950 - 960
  • [3] Antisense oligonucleotides in the treatment of bladder cancer
    Glackin, AJ
    Gray, SB
    Johnston, SR
    Duggan, BJ
    Williamson, KE
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2005, 5 (01) : 67 - 77
  • [4] Antisense oligonucleotides strategy in the treatment of hypertension
    Kagiyama, S
    Kagiyama, T
    Phillips, MI
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2001, 3 (03) : 258 - 264
  • [5] Antisense oligonucleotides for the treatment of neurodegenerative diseases
    Zhao, Hien T.
    Kordasiewicz, Holly
    Norris, Dan
    Smith, Anne
    Lane, Roger
    Bennett, C. Frank
    Swayze, Eric
    PRION, 2019, 13 : 94 - 95
  • [6] Antisense Oligonucleotides for the Study and Treatment of ALS
    Boros, Benjamin D.
    Schoch, Kathleen M.
    Kreple, Collin J.
    Miller, Timothy M.
    NEUROTHERAPEUTICS, 2022, 19 (04) : 1145 - 1158
  • [7] Antisense Oligonucleotides: A Unique Treatment Approach
    Krishnan, Abhinaya V.
    Mishra, Devendra
    INDIAN PEDIATRICS, 2020, 57 (02) : 165 - 171
  • [8] Antisense Oligonucleotides for the Treatment of Hypertriglyceridemia and Hyperlipoproteinemia(a)
    Hanssen R.
    Gouni-Berthold I.
    Current Pharmacology Reports, 2017, 3 (6) : 458 - 468
  • [9] Treatment of Usher syndrome with antisense oligonucleotides
    Lentz, Jennifer
    Flaat, Mette
    Jodelka, Francine
    Hinrich, Anthony
    Zhou, Yongdong
    McCaffery, Kate
    Duelli, Dominik
    Bazan, Nicolas
    Rigo, Frank
    Hastings, Michelle
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [10] Antisense Oligonucleotides: A Unique Treatment Approach
    Abhinaya V. Krishnan
    Devendra Mishra
    Indian Pediatrics, 2020, 57 : 165 - 171